对此，Shilpa Medicare的董事总经理Vishnukant Bhutada表示：“我们对SEC的批准感到非常高兴，并期待尽快获得市场授权。我们致力于与监管机构紧密合作，尽快将这一创新疗法带给患者，计划在即将到来的财年内在印度上市。” ...

Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), a leading API and formulation manufacturer, announces that the Subject Expert Committee (SEC) of CDSCO has approved its Investigational New Drug ...

UDCA 是肝脏自然产生的一种胆汁酸，一直以来主要用于治疗各种肝脏疾病，像原发性胆汁性胆管炎（Primary Biliary Cholangitis，PBC）、原发性硬化性胆管炎（Primary Sclerosing Cholangitis，PSC）和非酒精性脂肪性肝病（Nonalcoholic Fatty Liver Disease，NAFLD）等。不过，它对心血管 ...

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in Western countries. It encompasses a wide spectrum of liver lesions, from pure steatosis to end-stage liver disease with ...

Left untreated, NAFLD can progress to non-alcoholic steatohepatitis (NASH), a severe and potentially fatal condition. Shilpa Medicare Ltd. had earlier completed phase-3 clinical studies of this novel ...

Based on the association of CVD, diabetes and metabolic syndrome with the development and progression of NAFLD, the management of NAFLD should include aggressive management of cardiovascular risk ...

Further worrisome are recent data showing a high prevalence of NAFLD in obese Indian children.” Today, an increasing number of children are affected by Non-Alcoholic Fatty Liver Disease.